AR and central nervous system cancer: A 95% downregulation of SVIP expression, from NC to high-grade gliomas (WHO III and IV) was observed (Figure 1A); consecutively, the AR expression increased as the tumor grade progressed, irrespective of the gender (Figure 1A).